March 26 (Reuters) - Imv Inc IMV.TO :
* INITIAL PHASE 2 DATA FROM AN IMV CLINICAL STUDY CONTINUES TO DEMONSTRATE DPX-SURVIVAC'S PRIOR TREND AS A POTENTIAL MONOTHERAPY TREATMENT FOR ADVANCED OVARIAN CANCER
* IMV INC - 83% OF SUBJECTS (5 OF 6) SHOW STABLE DISEASE (SD), INCLUDING TWO TUMOR REGRESSIONS
* IMV INC - 80% (4 OF 5) WITH STABLE DISEASE ARE IN SUBJECTS WITH A LOWER BASELINE TUMOR BURDEN (BTB)